Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Genotype-guided Clear all
Completed Phase 1 Interventional

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

NCT01643499
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Duct Cell Adenocarcinoma of the Pancreas, Intestinal Adenocarcinoma of the Stomach, Localized Unresectable Adult Primary Liver Cancer, Metastatic Carcinoma of Unknown Primary, Metastatic Extrahepatic Bile Duct Cancer, Mixed Adenocarcinoma of the Stomach, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Newly Diagnosed Carcinoma of Unknown Primary, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Gastric Cancer, Stage IIIC Rectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Gallbladder Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Gallbladder Cancer, Stage IVB Rectal Cancer, Unresectable Extrahepatic Bile Duct Cancer
Interventions
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery

NCT03943927
View directory record Official record
Conditions
Post-operative Atrial Fibrillation
Interventions
Guided Metoprolol Management
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 9, 2026, 12:24 PM EDT
Terminated No phase listed Observational

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

NCT01465516
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain

NCT03637998
View directory record Official record
Conditions
Chronic Low Back Pain, Self-Management
Interventions
Problem-solving Pain to Enhance Living Well (PROPEL)
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms
Interventions
tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

NCT02333188
View directory record Official record
Conditions
Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma, Gallbladder Carcinoma, Gastric Adenocarcinoma, Malignant Gastrointestinal Neoplasm, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Ampulla of Vater Cancer, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Gastric Cancer, Stage IV Ampulla of Vater Cancer, Stage IV Gallbladder Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer
Interventions
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Leucovorin Calcium, Irinotecan Hydrochloride, Fluorouracil, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients

NCT01183494
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI, Avastin, Irinotecan
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

NCT04702113
View directory record Official record
Conditions
Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions
Cipherome Lighthouse Pilot
Diagnostic Test
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 2 Interventional

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

NCT01356160
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 9, 2026, 12:24 PM EDT
Not listed Not applicable Interventional

Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT

NCT02120729
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genotype-guided care
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 2 Interventional

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

NCT01371578
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional

A PK/PD Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression

NCT02286440
View directory record Official record
Conditions
Depression
Interventions
AssureRx GeneSight genotyping results, Treatment as usual
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 9, 2026, 12:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study

NCT05216042
View directory record Official record
Conditions
Cardiovascular Diseases, Natriuretic Peptides, Cardiometabolic Diseases, Energy Expenditure, Glucose Metabolism, Exercise, Obesity
Interventions
Study diet, Exercise capacity VO2 max determination, Exercise Challenge, Glucose Challenge
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Precision Medicine Guided Treatment for Cancer Pain

NCT02664350
View directory record Official record
Conditions
Pain, CYP2D6 Polymorphism
Interventions
CYP2D6, Brief Pain Inventory-Short Form (BPI-SF), M.D. Anderson Symptom Inventory (MDASI), OPRM1
Genetic · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

NCT00927862
View directory record Official record
Conditions
Thromboembolism
Interventions
IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
Genetic · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 9, 2026, 12:24 PM EDT
Active, not recruiting Not applicable Interventional

CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

NCT06565546
View directory record Official record
Conditions
Ventral Hernia
Interventions
Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin, Acetaminophen and Gabapentin: standard postoperative pain medications
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional Results available

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

NCT02634177
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Assay-guided treatment (AGT), Treatment-as-usual (TAU)
Genetic · Other
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional Results available

Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

NCT03534063
View directory record Official record
Conditions
Pain, Postoperative
Interventions
CYP2D6-guided opioid therapy
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gainesville, Florida • Summerfield, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Phase 3 Interventional

Clarification of Optimal Anticoagulation Through Genetics

NCT00839657
View directory record Official record
Conditions
Stroke, Venous Thrombosis, Atrial Fibrillation, Atrial Flutter
Interventions
Genotype-guided dosing algorithm for warfarin, Clinical-guided dosing algorithm for warfarin
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 9, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Breastfeeding Self-Management for Nipple and Breast Pain

NCT03392675
View directory record Official record
Conditions
Breastfeeding, Breast Pain
Interventions
Self-monitoring of BF and intervention
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Farmington, Connecticut • Manchester, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 9, 2026, 12:24 PM EDT